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Abstract. – OBJECTIVE: Although previous re-
search has reported beneficial effects of statins 
on infectious diseases, these have yet to be con-
cluded. Therefore, we conducted an umbrel-
la review to provide a comprehensive under-
standing of the strength of evidence and validi-
ty of claimed associations between statins (hy-
droxymethyl glutaryl-CoA reductase inhibitors) 
and infectious diseases.
MATERIALS AND METHODS: We conducted 
an umbrella review and re-analyzed data from 
meta-analyses of randomized controlled trials 
and observational studies on associations be-
tween statin use and different infectious dis-
eases such as bacteremia/sepsis and pneu-
monia. We also evaluated the level of evidence 
for each re-analyzed outcome based on the cri-
teria using p-values of random and fixed-ef-
fects, 95% prediction intervals, small-study ef-
fects, between-study heterogeneity, and con-
cordance between the effect estimate of the 
largest study and summary estimates of the 
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meta-analysis. Moreover, publication bias was 
also examined.
RESULTS: Through a systematic literature 
search, we obtained 14 eligible articles includ-
ing 25 meta-analyses. All 4 meta-analyses on 
overall infection, 3 out of 14 meta-analyses on 
bacteremia/sepsis, and 5 out of 7 meta-analyses 
on pneumonia demonstrated that statin use was 
associated with reduced mortality due to infec-
tions (caused by infections). Nonetheless, most 
significant results only showed a weak level of 
evidence, and one study with convincing evi-
dence prior to adjustment also showed weak ev-
idence after adjustment.
CONCLUSIONS: The present review identi-
fied a protective effect of statins on infection-re-
lated mortality, but all available studies had a 
weak level of evidence. Therefore, further stud-
ies with a strong level of evidence are needed, 
and it is also necessary to investigate the types 
of statins and to study clinical outcomes other 
than mortality to gain further insights.
Key Words:
Statin, HMG (hydroxymethyl glutaryl)-CoA reduc-
tase, Infectious disease, Pneumonia, bacteremia, Sep-
sis, mortality, Umbrella review.
Introduction
In modern medicine, several medications 
have brought significant changes to health care. 
Statins, which inhibit the HMG (hydroxymeth-
yl glutaryl)-CoA reductase, are one such med-
ication, and have contributed to a reduction in 
morbidity and mortality from cardio-cerebrovas-
cular diseases1,2. In addition, a large number of 
studies have demonstrated the pleiotropic effects 
of statins beyond cholesterol lowering action3. 
For example, statins exert beneficial effects on 
the cardiovascular system through anti-oxidative4 
and anti-inflammatory actions5, as well as an an-
ti-tumor effect via inhibiting specific metabolic 
pathways6.  Interestingly, statins also have an 
anti-infective potential. Although the anti-infec-
tive effect of statins may not be widely known, 
historically, the development of statins began as 
an attempt to find new antibiotics from fungi7. 
Therefore, it is justifiable to explore the potential 
anti-infective effect of statins.
Although the exact underlying mechanism has 
not yet been documented, many clinical studies 
including randomized controlled trials (RCTs) 
or observational studies have supported the pro-
tective effect of statins in patients suffering from 
different types of infection. However, compre-
hensive review studies to verify the clinical ben-
efits of statins in infected patients are scarce. In 
this study, to discern and appraise the strength of 
the evidence of statin efficacy on reducing mor-
tality in patients with infection, we carried out 
an umbrella review and thereby comprehensively 
re-analyzed the data of meta-analyses of RCTs 
and observational studies.
Materials and Methods
We performed an umbrella review of me-
ta-analyses and systematic reviews studying the 
effects and associations between the use of statin 
and all-cause mortality in patients with different 
etiologies of infection. This umbrella review was 
conducted according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines8.
Literature Search
We performed our search using the following 
keywords: ‘(hydroxymethyl glutaryl-coa reduc-
tase inhibitor OR statin) AND (mortality OR 
infection) AND (meta-analysis OR systematic 
review)’. We limited our search to articles written 
in English. We performed the search in January 
2020. Meta-analyses of either RCTs or observa-
tional studies were included in our search strate-
gy. Each retrieved article was reviewed in detail 
including the title, abstract, and the full texts. 
Subsequently, inclusion and exclusion criteria 
were applied in the decision to include or exclude 
the articles. A supplementary EMBASE database 
search was also conducted for completion. Eligi-
ble meta-analyses that did not overlap with the 
PubMed search were included. 
Eligibility Criteria and Data Extraction
Meta-analyses and systematic reviews of both 
RCTs and observational studies (cohort and 
case-control studies) investigating the associa-
tion between statin use and mortality rates of 
patients with infection were included. Articles 
containing multiple meta-analyses were included, 
and each respective meta-analysis was assessed 
independently for inclusion. Review articles of in 
vitro studies and genetic studies were excluded. 
Two of our investigators (G.H.J. and J.I.S) in-
dividually performed data search and extraction. 
Discrepancies were resolved via consensus. In-
formation was gathered regarding the articles’ 
first author, year of publication, infection etiol-
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ogy, study design, number of included studies, 
mortality rates, total number of participants, and 
random effects with a 95% confidence interval 
(CI). Raw data of each individual study were an-
alyzed considering all data on mortality rates of 
patients with infection, statins use and study de-
sign. Results of articles containing both RCTs and 
observational studies were reported separately.
Statistical Analysis
Each meta-analysis that satisfied the inclu-
sion criteria was analyzed and the association 
between statin use and mortality among patients 
with infections was reported. In the case of 
overlapping meta-analyses, the individuals were 
combined according to mortality, infection type, 
and study design. In this case, a re-meta-analysis 
(to verify further this term) was conducted after 
eliminating overlapping individual studies. Sum-
mary effect size was reported with a 95% CI, 
and p-value with both random- and fixed-effects. 
All re-analyses in this study were performed us-
ing the Comprehensive Meta-Analysis software 
ver.3.3.070 (Borestein, NH, USA).
Estimation of Summary Effects and 
Estimation of Prediction Interval
All individual studies were re-examined for 
each meta-analysis. The summary effects and 
95% CI using both random- and fixed-effects 
methods were assessed. We also reported the 
95% prediction interval (PI), which addresses 
the dispersion of effects and also considers the 
in-between-study heterogeneity. Our CI reflected 
the accuracy of the mean.
Evaluation of Between-Study 
Heterogeneity and Small Study Effects
The I2 metric of inconsistency and the p-value 
of the Cochrane Q test were used to assess het-
erogeneity across the studies. I2 values of < 50% 
(low), 50-75% (moderate), and >75% (high) were 
used to describe heterogeneity. Egger’s regres-
sion test was used to interpret publication bias-
es. Small-study effects were used for detecting 
publication and reporting bias. An article was 
considered to have a small-study effect when 
Egger’s test had p-value < 0.10 in random-effects 
meta-analyses.
Determination of the Level of Evidence
The evidence level of the association between 
statin uses and mortality among patients with 
infection was determined for each meta-analy-
sis and re-analysis of the pooled meta-analysis. 
The criteria were based on a number of factors, 
including statistical significance by random and 
fixed-effects p-values, 95% PI, small-study ef-
fects, between-study heterogeneity, and concor-
dance between the effect estimate of the largest 
study and summary estimate of the meta-anal-
ysis. 
The criteria were stratified as follows:
Convincing evidence: (1) Statistical signifi-
cance for the random- and fixed-effects at p 
< 0.001, (2) No small study effects or large 
between-study heterogeneity, (3) 95% PI re-
jected the null hypothesis, (4) Concordance 
between the effect estimate of the largest study 
and the summary effect of the random-effects 
meta-analyses.
Suggestive evidence: (1) Statistical significance 
of random effect at p < 0.05, (2) 95% PI in-
cluded the null hypothesis, (3) No small study 
effects or large between-study heterogeneity.
Weak evidence: (1) Statistical significance of 
random effect at p < 0.05, (2) Small study 
effects or large between-study heterogeneity 
were found.
Non-significant association: There was no sta-
tistical significance for random effect of me-
ta-analysis (p >0.05).
In case of large heterogeneities, the results 
were reassessed to resolve whether it was second-
ary to differences in the direction of the effect or 
if it could be due to differences in the size of the 




A total of 315 records were retrieved by the 
literature search. Among them, the full-text of 
46 records was reviewed for eligibility, and 14 
articles were considered eligible, corresponding 
to 25 meta-analyses (Figure 1)9-22. Six articles 
were meta-analysis of RCTs10,13,17-19,21, 4 were 
of observational studies9,11,15,20, and the other 
4 were of both RCTs and observational stud-
ies12,14,16,22. We conducted re-analysis on all in-
cluded meta-analyses and reported the outcome 
along with what was reported in each study. 
We classified the meta-analyses into 3 groups 
according to the types of diseases: (1) overall 
infection, (2) bacteremia/sepsis, and (3) pneu-
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monia. Four meta-analyses were classified into 
the overall infection group, corresponding to 
102 individual studies and 3,346,104 patients. 
Fourteen meta-analyses were classified into the 
bacteremia/sepsis group, corresponding to 85 
individual studies and 37,505 patients. Seven 
meta-analyses were classified into the pneu-
monia group, corresponding to 57 individual 
studies and 3,199,662 patients. Moreover, the 
meta-analyses of the pneumonia group were 
once again classified according to the inclusion 
of studies that reported adjusted OR.
Association of Statin Use and 
Overall Infection
Four articles and corresponding 4 meta-analy-
ses including 2 RCTs and 4 observational studies 
investigated the relationship between statin use 
and overall infection (Table I). All the studies 
reported that statin use was associated with a 
reduced risk of all-cause mortality, and the same 
results were also found in our re-analysis. How-
ever, despite significant results, they only had a 
weak level of evidence.
Association of Statin Use and 
Bacteremia/Sepsis
There were 8 articles and corresponding 14 
meta-analyses regarding bacteremia and sepsis, 
including 66 RCTs and 19 observational studies 
(Table II). The primary outcome was all-cause 
mortality and in-hospital mortality. Three studies 
reported that statin use is associated with re-
duced mortality, and similar results were carried 
out with our re-analysis as well. However, all 
the studies showed only weak level of evidence. 
Figure 1. PRISMA flow chart of literature 
search.
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Table I. Statin therapy on overall infection.
 Author No Type Type   Type  Effect  Random Fixed       Small
 et al, of of of  Intervention/ of Model size effect effect   I2 p-value p-value 95% study
 year studies studies  patients Outcome Total metrics (reported) (reported) (re-analyzed) (re-analyzed) D/N/I* Egger (p-value) (random) (fixed) PI effects Evidence
Wan, 2014 26 OS Infection/ All-cause 55419/337648 RR Random 0.65 0.66 0.76 17/9/0 0.016 73.4 < 0.001 < 0.001 0.39- Yes Weak
   Sepsis mortality    (0.57-0.75) (0.57-0.76) (0.72-0.80)   (< 0.001)   1.12 
Ma, 2012 41 RCT, OS Infection All-cause 1205169/2628988 OR Random 0.70 0.71 0.85 22/18/1 0.00007 75.1 < 0.001 < 0.001 0.47- Yes Weak
  (CC, Cohort)  mortality    (0.64-0.77) (0.64-0.78) (0.83-0.87)   (< 0.001)   1.06  
Björkhem- 15 OS Bacterial All-cause 8611/113910 OR Random 0.53 0.53 0.60 12/3/0 0.015 66.9  < 0.001 < 0.001 0.26- Yes Weak
Bergman,    infection mortality    (0.42-0.66) (0.42-0.66) (0.54-0.67)   (< 0.001)   1.08  
2010                  
Janda, 2010 20 RCT, OS Infection All-cause 64229/265558 OR Random 0.49 0.57 0.63 15/5/0 0.026 69.5 < 0.001 < 0.001 0.29- Yes Weak
  (CC, Cohort)  mortality    (0.37-0.61) (0.47-0.69) (0.58-0.69)   (< 0.001)   1.14  
CAP: community-acquired pneumonia, CC: case-control, NA: not assessed, No: number, OS: observational study, OR: odds ratio, PI: prediction interval, RCT: randomized controlled trial, RR: relative risk, *Number of 
individual studies reporting; D: statistically significant decrease in mortality by statin therapy, N: not statistically significant effect of statin on mortality, I: statistically significant increase in mortality by statin therapy.
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Table II. Statin therapy on bacteremia/sepsis.
 Author No Type Type   Type  Effect  Random Fixed       Small
 et al, of of of  Intervention/ of Model size effect effect   I2 p-value p-value 95% study
 year studies studies  patients Outcome Total metrics (reported) (reported) (re-analyzed) (re-analyzed) D/N/I* Egger (p-value) (random) (fixed) PI effects Evidence
Chen, 2018 7 RCT Sepsis All-cause  1078/2159 RR Fixed 0.96 0.95 0.96 0/7/0 0.778 20 0.572 0.595 0.70- No No
    mortality    (0.83-1.11) (0.80-1.13) (0.83-1.11)   (0.28)   1.28  
    In-hospital                
Chen, 2018 5 RCT Sepsis All-cause  613/1246 RR Fixed 0.90 0.93 0.92 0/5/0 0.947 29 0.585 0.424 0.55- No No
    mortality    (0.73-1.11) (0.71-1.21) (0.75-1.12)   (0.23)   1.56  
    28-day    
Pertzov, 2018 13 RCT Sepsis All-cause  1201/2430 RR Fixed 0.96  0.94 0.95 0/13/0 0.237 4 0.420 0.462 0.78- No No
    mortality    (0.83-1.10) (0.82-1.09) (0.83-1.09)   (0.40)   1.14  
    30-day              
Pertzov, 2018 9 RCT Severe All-cause 1006/2040 RR Fixed 0.97 0.94 0.96 0/9/0 0.347 19 0.493 0.594 0.70- No No
   sepsis mortality    (0.84-1.12) (0.80-1.11) (0.84-1.11)   (0.27)   1.28  
    30-day              
Shrestha,  6 OS Bacteremia All-cause 905/7553 OR Random 0.49 0.50 0.67 3/3/0 0.003 67.6 0.004 <0.001 0.12- Yes Weak
2016    mortalit     (0.30-0.81) (0.31-0.81) (0.54-0.83)   (0.009)   2.03  
    In-hospital    
Quinn, 2016 4 RCT Sepsis All-cause 576/1171 RR Fixed 0.88 0.89 0.88 0/4/0 0.471 42.6 0.565 0.310 0.23- No No
    mortality    (0.70-1.12) (0.61-1.31) (0.70-1.12)   (0.156)   3.46  
    28-day    
Quinn, 2016 6 RCT Sepsis All-cause  1086/2175 RR Fixed 0.98 0.98 0.98 0/6/0 0.492 8.9 0.795 0.807 0.73- No No
    mortality    (0.85-1.14) (0.83-1.15) (0.85-1.14)   (0.359)   1.31  
    In-hospital                
Deshpande,  5 RCT Sepsis All-cause  819/1620 RR Random 1.04 1.04 1.04 0/5/0 0.246 0.0 0.680 0.680 0.78- No No
2015    mortality    (0.87-1.24) (0.87-1.24) (0.87-1.24)   (0.429)   1.38  
    In-hospital               
Deshpande,  3 RCT Sepsis All-cause 318/634 RR Random 0.93 0.93 1.00 0/3/0 0.422 56.6 0.845 0.998 0.00- No No
2015    mortality    (0.46-1.89) (0.46-1.89) (0.68-1.48)   (0.100)   1457.16  
    28-day              
Thomas,  4 RCT Severe All-cause  903/1802 RR Random 0.93 0.93 0.96 0/4/0 0.274 52.1 0.573 0.584 0.17- No No
2015   sepsis mortality    (0.72-1.20) (0.72-1.20) (0.82-1.12)   (0.099)   4.51  
    28-day              
Thomas,  4 RCT Severe sepsis All-cause 907/1818 RR Random 0.95 0.88 0.88 1/3/0 0.483 74.9 0.504 0.146 0.36- No No
2015    mortality    (0.72-1.27) (0.60-1.29) (0.74-1.05)   (0.008)   2.43  
    60-day     
Pasin, 2013 6 RCT Sepsis All-cause 423/862 RR Fixed 0.95 0.92 0.92 0/6/0 0.110 0.0 0.664 0.664 0.55- No No
    mortality    (0.74-1.21) (0.64-1.33) (0.64-1.33)   (0.947)   1.54  
Ma, 2012 6 OS   All-cause 900/7571 OR Random 0.40 0.39 0.77 5/1/0 0.0004 78.1 0.006 0.012 0.05- Yes Weak
  (Cohort) Bacteremia mortality    (0.20-0.78) (0.20-0.76) (0.63-0.94)   (< 0.001)   3.08  
Ma, 2012 7 OS  Sepsis All-cause 899/4424 OR Random 0.61 0.61 0.59 3/4/0 0.477 55.0 0.012 < 0.001 0.21- No Weak
  (Cohort)  mortality    (0.41-0.90) (0.41-0.90) (0.47-0.72)   (0.038)   1.74 
CC: case-control, No: number, OS: observational study, OR: odds ratio, PI: prediction interval, RCT: randomized controlled trial, RR: relative risk, *Number of individual studies reporting; D: statistically significant decrease 
in mortality by statin therapy, N: not statistically significant effect of statin on mortality, I: statistically significant increase in mortality by statin therapy.
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None of the studies, including individual studies, 
showed a positive association between statin use 
and mortality.
Association of Statin Use 
and Pneumonia
Four articles and corresponding 7 meta-anal-
yses investigated the relationship between statin 
use and pneumonia. The meta-analyses included 
57 individual studies, of which 4 were RCTs and 
53 were observational studies (Table III). Of the 
7 meta-analyses of studies with unadjusted OR, 5 
reported that statin therapy lowered the mortal-
ity of patients with pneumonia. Our re-analysis 
confirmed published results. Interestingly, one 
article reported different effects of statin use on 
mortality according to the severity of pneumonia. 
The article demonstrated a negative association 
in non-severe pneumonia (OR: 0.64; 95% CI: 
0.57-0.73), but not in severe pneumonia (OR: 1.03; 
95% CI 0.77-1.38).
We analyzed the studies with adjusted OR 
separately, and there were 6 meta-analyses from 
3 articles including 45 observational studies (Ta-
ble IV). None of the meta-analyses included 
RCTs. Among the 6 meta-analyses, 5 reported 
decrease in mortality with statin therapy, while 
our re-analysis showed that 4 meta-analyses had 
significant results.
In particular, while most meta-analyses that 
showed significant results had only weak level 
of evidence as in bacteremia and sepsis, one me-
ta-analysis had a convincing level of evidence. 
Nevertheless, the convincing level of evidence 
was not found in the analysis of studies with ad-
justed OR. 
Discussion
Statins are one of the most prescribed drugs in 
the world. Its pleiotropic effects are variable rang-
ing from anti-lipid to anti-inflammatory actions23. 
Thus, many researchers have tried to find the 
novel role of statin beyond anti-lipid effects for 
several decades. Among them, an anti-bacterial 
effect is one of the important properties of statins. 
Many in vitro and in vivo studies have demon-
strated the anti-bacterial and anti-viral effects of 
statins24,25. According to those studies, certain 
types of statins have a bacteriostatic effect and 
synergies with antibiotics through multiple mech-
anisms. The mechanisms of action have not been 
clearly elucidated, but it seems that inhibiting 
infectious organisms do not depend on reducing 
HMG-CoA reductase. Instead, many studies have 
indicated that the anti-infective effect of statins 
is due to the multifaceted action26, including in-
teraction with bacterial cell walls24, synergy with 
antibiotics27,28, attenuating virulence factors25, 
immune enhancements29 and anti-inflammatory 
actions30,31. However, despite many experimental 
studies demonstrating the antibiotic effects of 
statins, the clinical effects on infectious diseases 
in humans have yet to be concluded. In addition, 
the results of many clinical trials are conflicting, 
and systemic reviews and meta-analyses of those 
studies do not give a clear answer as well32,33.
In this study, we investigated the relationship 
between statin treatment and mortality in pa-
tients with infectious diseases by analyzing 25 
meta-analyses from 14 articles. As a result, we 
were able to identify clinical benefits of statins on 
serious infections such as sepsis and pneumonia. 
Nonetheless, the evidence for significant results 
was mostly weak. One study showed convincing 
evidence in pneumonia patients, but this was no 
longer the case after adjustment. Our analyses 
demonstrated that most weak levels of evidence 
were primarily due to large between-study het-
erogeneity. In addition, small-study effects and 
95% PI including the null hypothesis were also 
thought to contribute to the lack of evidence. 
Therefore, despite positive effects of statins on 
infections, our study suggests that further studies 
should be required to obtain more convincing 
evidence.
Importantly, when analyzing according to 
the type of infectious disease, relatively more 
meta-analyses showed significant results in the 
pneumonia group. Five out of 7 meta-analyses 
had significant results in the analysis of studies 
with unadjusted OR, and 4 out of 6 were signif-
icant with adjusted OR. In contrast, only 3 out 
of 14 meta-analyses had significant results in the 
bacteremia and sepsis group. In this regard, we 
could understand such results based on the fact 
that pneumonia usually has a less severe clinical 
course and a lower mortality rate than bactere-
mia and sepsis. Actually, although many studies 
have reported the clinical effects of statins on 
infections, it seems unlikely that such effects are 
also significantly related to serious infections. In 
particular, as the outcome of sepsis is the result 
of a variety of complex clinical situations and 
treatments, it is not easy to prove that only one 
factor, such as statin use, could lower mortali-
ty34-36. We believe that the results of our research 
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Table III. Statin therapy on pneumonia (studies reporting unadjusted OR data).
 Author No Type Type   Type  Effect  Random Fixed       Small
 et al, of of of  Intervention/ of Model size effect effect   I2 p-value p-value 95% study
 year studies studies  patients Outcome Total metrics (reported) (reported) (re-analyzed) (re-analyzed) D/N/I* Egger (p-value) (random) (fixed) PI effects Evidence
Jia, 2015 11 OS Non-severe All-cause NA/195466 OR NA 0.70 0.64 0.69 7/4/0 0.114 78.2 < 0.001 < 0.001 0.43- No Weak
  (CC, Cohort) pneumonia mortality    (0.67-0.73) (0.57-0.73) (0.66-0.73)   (< 0.001)   0.95 
Jia, 2015 8 RCT, OS Severe All-cause 901/2755 OR NA 1.05 1.03 1.05 0/7/1 0.338 41.3 0.835 0.626 0.50- No No
  (Cohort) pneumonia mortality    (0.86-1.28) (0.77-1.38) (0.86-1.28)   (0.103)   2.11  
Cheng, 2014 3 OS) Pneumonia All-cause 26750/178764 OR Random 0.86 0.86 0.69 1/2/0 0.216 85.4 0.517 < 0.001 0.00- No No
  (CC, Cohort  mortality    (0.56-1.34) (0.55-1.35) (0.64-0.74)   (0.001)   186.57  
    In-hospital                
Cheng, 2014 5 OS (CC,  Pneumonia All-cause 1899/35716 OR Random 0.44 0.44 0.55 3/2/0 0.110 67.3 < 0.001 < 0.001 0.11- No Weak
  Cohort)  mortality    (0.29-0.67) (0.29-0.67) (0.47-0.64)   (0.016)   1.70  
    30-day            
Cheng, 2014 4 OS (Cohort) Pneumonia All-cause  3230/39550 OR Random 0.49 0.49 0.54 4/0/0 0.333 95.5 0.010 < 0.001 0.04- No Weak
    mortality    (0.29-0.84) (0.29-0.84) (0.48-0.59)   (< 0.001)   6.35
    long-term               
Chopra, 2012 10 RCT, OS CAP All-cause 26825/167151 OR Random 0.62 0.61 0.64 6/4/0 0.125 49.2 < 0.001 < 0.001 0.44- No Convincing
  (CC, Cohort)  mortality    (0.54-0.71) (0.53-0.70) (0.61-0.68)   (0.039)   0.85  
Ma, 2012 16 OS Pneumonia All-cause  1186015/2580260 OR Random 0.69 0.70 0.86 12/4/0 0.001 83.0 < 0.001 < 0.001 0.47- Yes Weak
  (CC, cohort)  mortality    (0.62-0.78) (0.62-0.78) (0.83-0.88)   (<0.001)   1.02  
CAP: community-acquired pneumonia, CC: case-control, NA: not assessed, No: number, OS: observational study, OR: odds ratio, PI: prediction interval, RCT: randomized controlled trial, RR: relative risk, * Number of 
individual studies reporting; D: statistically significant decrease in mortality by statin therapy, N: not statistically significant effect of statin on mortality, I: statistically significant increase in mortality by statin therapy.
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Table IV. Statin therapy on pneumonia (studies reporting adjusted OR data).
 Author No Type Type   Type  Effect  Random Fixed       Small
 et al, of of of  Intervention/ of Model size effect effect   I2 p-value p-value 95% study
 year studies studies  patients Outcome Total metrics (reported) (reported) (re-analyzed) (re-analyzed) D/N/I* Egger (p-value) (random) (fixed) PI effects Evidence
Jia, 2015 15 OS Non-severe All-cause NA/309307 OR NA 0.78 0.71 0.78 12/3/0 0.010 74.3 < 0.001 < 0.001 0.50- Yes Weak
  (CC, cohort) pneumonia mortality    (0.75-0.82) (0.64-0.79) (0.75-0.82)   (< 0.001)   1.02  
Jia, 2015 3 OS Severe  All-cause 144/1104 OR NA 0.92 0.86 0.92 0/3/0 0.377 41.0 0.719 0.762 0.00- No No
  (Cohort) pneumonia  mortality    (0.53-1.60) (0.37-1.99) (0.53-1.60)   (0.184)   3356.59  
Cheng, 2014 3 OS  Pneumonia All-cause 26750/178764 OR Fixed 0.89 0.84 0.89 2/1/0 0.359 50.9 0.156 0.007 0.07- No No
  (CC, cohort)  mortality    (0.81-0.97) (0.66-1.07) (0.81-0.97)   (0.130)   10.65  
    In-hospital              
Cheng, 2014 9 OS  Pneumonia All-cause  NA/79499 OR Random 0.59 0.59 0.76 9/0/0 0.002 81.1 < 0.001 < 0.001 0.32- Yes Weak
  (CC, cohort)  mortality    (0.48-0.73) (0.48-0.73) (0.71-0.81)   (< 0.001)   1.10   
    30-day               
Cheng, 2014 4 OS Pneumonia All-cause  3230/39550 OR Random 0.65 0.65 0.69 3/1/0 0.206 61.9 < 0.001 < 0.001 0.25- No Weak
  (Cohort)  mortality    (0.51-0.82) (0.51-0.82) (0.62-0.78)   (0.049)   1.65  
    long-term                 
Chopra, 2012 11 OS (CC, CAP All-cause 26825/167151 OR Random 0.66 0.66 0.79 8/3/0 0.006 72. < 0.001 < 0.001 0.38- Yes Weak
  cohort)  mortality     (0.55-0.79) (0.55-0.79)  (0.73-.084)    (<0.001)   1.13  
CAP: community-acquired pneumonia, CC: case-control, NA: not assessed, No: number, OS: observational study, OR: odds ratio, PI: prediction interval, RCT: randomized controlled trial, RR: relative risk, *Number of 
individual studies reporting; D: statistically significant decrease in mortality by statin therapy, N: not statistically significant effect of statin on mortality, I: statistically significant increase in mortality by statin therapy.
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can be interpreted in that context. Furthermore, 
even in the case of pneumonia, one study showed 
a significant inverse association between statin 
and mortality in non-severe pneumonia, whereas 
this was not the case in severe pneumonia. There-
fore, in order to obtain the exact effect of statins 
on infections, the type and severity of infectious 
diseases should be considered.
Our study has some limitations. First, we could 
not identify the effects of individual statins on 
infection. Previous studies28,37 showed that sim-
vastatin, atorvastatin, and rosuvastatin have an-
ti-bacterial activity, while other statins do not. 
Therefore, studies conducted without distinguish-
ing the type of statins are expected to fundamen-
tally underestimate the anti-infective effect of 
statins. Second, since our goal was to identify the 
benefits of the respective statin on infection-relat-
ed mortality, we could not examine other clinical 
outcomes such as the duration of antibiotics or 
intensive care unit stay. If we focus only on mor-
tality and judge the clinical effects of statins, we 
may miss out on a number of other clinical effects 
in infectious diseases. Finally, we could not be 
sure that the beneficial effect of statin on survival 
through anti-lipid action was properly excluded in 
the analysis. It was believed that RCTs generally 
controlled such confounding factor, while it was 
uncertain whether the factor was properly adjust-
ed in observational studies.
Conclusions
Our umbrella review study comprehensive-
ly reanalyzed the existing meta-analyses that 
investigated the beneficial effects of statins on 
sepsis or pneumonia. We could identify the 
beneficial effects of statins on infection-related 
mortality, but the effects have only weak evi-
dence. Therefore, further research is needed to 
verify the protective effect of statins on infec-
tions. In addition, it is necessary to distinguish 
the type of statin and to assess clinical outcomes 
other than mortality.
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